VASOPHARM
vasopharm is a biopharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases and their consequences. In this area, the company is focused on the development of therapeutics influencing the bioavailability of nitric oxide (NO), a cellular signalling molecule involved in many physiological and pathological processes. vasopharm’s drug candidate VAS203 is an allosteric NO synthase inhibitor and represents a completely new class of modulators of nitric oxide synthase (NOS) enzymes. It rapidly lowers excessive NO production in cerebral vessels and tissues, thereby preventing life-threatening increases in intracranial pressure and associated inflammatory processes following traumatic brain injury.
VASOPHARM
Industry:
Biotechnology Medical Therapeutics
Founded:
1998-07-01
Address:
Würzburg, Bayern, Germany
Country:
Germany
Website Url:
http://www.vasopharm.com
Total Employee:
1+
Status:
Active
Contact:
49 931 35 90 99 0
Total Funding:
63.23 M USD
Technology used in webpage:
Euro SPF Google Maps Google Maps API
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Current Advisors List
Board_member
2019-07-01
Board_member
2007-01-01
Current Employees Featured
Ulrich Walter Co-Founder @ Vasopharm
Co-Founder
1998-01-01
Frank Tegtmeier Chief Scientific Officer @ Vasopharm
Chief Scientific Officer
Christian Wandersee Chief Executive Officer & Co-Founder @ Vasopharm
Chief Executive Officer & Co-Founder
Founder
Investors List
Rington Holdings
Rington Holdings investment in Private Equity Round - Vasopharm
Hanseatic Asset Management
Hanseatic Asset Management investment in Private Equity Round - Vasopharm
Bayern Kapital
Bayern Kapital investment in Private Equity Round - Vasopharm
EF Investments
EF Investments investment in Private Equity Round - Vasopharm
HeidelbergCapital Private Equity
HeidelbergCapital Private Equity investment in Private Equity Round - Vasopharm
Future Capital Development Fund
Future Capital Development Fund investment in Private Equity Round - Vasopharm
Entrepreneurs Fund
Entrepreneurs Fund investment in Series G - Vasopharm
Hanseatic Asset Management
Hanseatic Asset Management investment in Series G - Vasopharm
Bayern Kapital
Bayern Kapital investment in Series G - Vasopharm
Fort Rock Capital
Fort Rock Capital investment in Series G - Vasopharm
Official Site Inspections
http://www.vasopharm.com
- Host name: 84.38.79.51
- IP address: 84.38.79.51
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Vasopharm"
Vasopharm - Crunchbase Company Profile & Funding
Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms. View contacts for Vasopharm to access new …See details»
veriNOS pharmaceuticals - Neuroscience for your brain
Our management team consists of experienced biopharma executives with complementary backgrounds, including corporate governance, finance, medicine and science.See details»
Vasopharm - Products, Competitors, Financials, Employees, …
Vasopharm specializes in the development of neuroprotective treatments within the pharmaceutical industry. The company's main focus is on creating drugs like Ronopterin, …See details»
vasopharm - VentureRadar
Website: http://vasopharm.com. Develops novel therapeutics for cerebro- and cardiovascular diseases, focusing on discovery and treatment advancements within the German …See details»
veriNOS Pharmaceuticals - Craft
VeriNOS Pharmaceuticals (formerly known as Vasopharm) is a company that specializes in researching and developing therapeutics and the treatment of cerebral and cardiovascular …See details»
Vasopharm - Contacts, Employees, Board Members, Advisors
Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.See details»
Vasopharm - Crunchbase
Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.See details»
vasopharm - Würzburg
Die vasopharm GmbH, eine Ausgründung des Universitätsklinikums Würzburg, ist ein biopharmazeutisches Unternehmen mit dem Fokus auf der Erforschung und Entwicklung …See details»
Reinhard Schinzel - Head, Research & Drug Safety Operations
Prof Dr. Reinhard Schinzel is Head of Research & Drug Safety Operations and in particular responsible for drug safety and pharmacovigilance in all clinical trials conducted by …See details»
John Stover - Chief Medical Officer at Vasopharm | The Org
Prof Dr. John Stover joined vasopharm in 2021 as a freelance consultant. He worked for more than 15 years in the fields of intensive care medicine and neurosurgery at the University …See details»
vasopharm GmbH | Insights
Jul 12, 2019 · The NOSTRA III study of Germany’s Vasopharm GmbH ’s inducible nitric oxide synthase inhibitor ronopterin (VAS203) has missed its primary endpoint in patients with …See details»
vasopharm GmbH Announces Post Hoc Analyses of Clinical Trials …
WÜRZBURG, Germany, Feb. 8, 2022 /PRNewswire/ -- vasopharm GmbH ("vasopharm"), a privately-held biopharmaceutical company focusing on novel therapeutics to treat …See details»
German biotech company vasopharm raises €9.5 million to …
Jul 11, 2019 · Würzburg-based vasopharm GmbH is a biopharmaceutical company developing a develop novel therapeutics to treat TBIs. The company has announced the successful raise of …See details»
Vasopharm - Funding, Financials, Valuation & Investors
Vasopharm is focused on the R&D of novel therapeutics for the treatment of cerebro and cardiovascular diseases and their symptoms.See details»
vasopharm Announces EUR 20 Million Fundraising to Progress …
Jan 21, 2016 · vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced it has …See details»
Vasopharm drug could limit damage caused by brain injuries
Sep 6, 2016 · Based in Wurzburg in Germany, Vasopharm has developed ronopterin (VAS203), and believe the drug can prevent damage being done to the brain when infused between six …See details»
vasopharm GmbH Announces Results of the NOSTRA III Traumatic …
WÜRZBURG, Germany, June 3, 2021 /PRNewswire/ -- vasopharm GmbH, a privately-held biopharmaceutical company focusing on novel therapeutics for the treatment of …See details»
Make It Ten: vasopharm. In Make It Ten â„–5 we spoke with
In Make It Ten №5 we spoke with Christian Wandersee, CEO of vasopharm, the most recent investment out of our CV IV fund.See details»
Efficacy of VAS203 (Ronopterin) in Patients With Moderate and …
10 May 2022 Results published in the vasopharm BIOTECH Media Release. You need to be a logged in subscriber to view this content. If your organization has a subscription then there are …See details»
Vasopharm's brain injury drug fails to improve patient outcomes in ...
Jun 3, 2021 · Nearly 14 years after completing the first-in-human study, Vasopharm has hit another major snag with its lead candidate ronopterin, which has failed to improve the …See details»